Literature DB >> 27148789

Psychometric properties of the Leiden Index of Depression Sensitivity (LEIDS).

Ericka Solis1, Niki Antypa1, Judith M Conijn1, Henk Kelderman1, Willem Van der Does1.   

Abstract

The Leiden Index of Depression Sensitivity (LEIDS; Van der Does, 2002a) is a self-report measure of cognitive reactivity (CR) to sad mood. The LEIDS and its revised version, LEIDS-R (Van der Does & Williams, 2003), reliably distinguish between depression-vulnerable and healthy populations. They also correlate with other markers of depression vulnerability, but little is known about the other psychometric properties. Our aim was to examine the factor structure and validity of the LEIDS-R. We used data from the Netherlands Study of Depression and Anxiety (NESDA; N = 1,696) and a student sample (N = 811) for exploratory and confirmatory factor analysis (EFA and CFA, respectively). CFA showed that model fit of the 6-factor structure was satisfactory in the NESDA sample, but some factors were highly correlated. After removing 4 poor items, EFA yielded an alternative 5-factor structure and could not replicate the original 6-factor model. Testing for measurement invariance across recruitment groups of NESDA showed support for strong invariance. Due to high interfactor correlations, a bifactor model with 1 general factor and 5 specific factors was fitted in 2 samples. This model supported use of a general factor, but high factor loadings in specific factors supported retaining a 5-subscale structure. Higher scores on the general factor were associated with a history of depression, especially in participants with a history of comorbid anxiety. We concluded that the LEIDS-R has good psychometric properties. A modified version, LEIDS-RR, comprised of 5 subscales and a total CR score, is recommended for future research. One of the subscales is suitable as a short form. (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Year:  2016        PMID: 27148789     DOI: 10.1037/pas0000326

Source DB:  PubMed          Journal:  Psychol Assess        ISSN: 1040-3590


  6 in total

1.  Simultaneously examining negative appraisals, emotion reactivity, and cognitive reactivity in relation to depressive symptoms in children.

Authors:  David A Cole; Rachel L Zelkowitz; Elizabeth A Nick; Sophia R Lubarsky; Jason D Rights
Journal:  Dev Psychopathol       Date:  2019-10

2.  Extruded Wheat Bran Consumption Increases Serum Short-Chain Fatty Acids but Does Not Modulate Psychobiological Functions in Healthy Men: A Randomized, Placebo-Controlled Trial.

Authors:  Boushra Dalile; Danique La Torre; Polona Kalc; Francesca Zoppas; Chiara Roye; Chrystel Loret; Lisa Lamothe; Gabriela Bergonzelli; Christophe M Courtin; Bram Vervliet; Lukas Van Oudenhove; Kristin Verbeke
Journal:  Front Nutr       Date:  2022-05-26

3.  Improving treatment for patients with childhood abuse related posttraumatic stress disorder (IMPACT study): protocol for a multicenter randomized trial comparing prolonged exposure with intensified prolonged exposure and phase-based treatment.

Authors:  D A C Oprel; C M Hoeboer; M Schoorl; R A De Kleine; I G Wigard; M Cloitre; A Van Minnen; W Van der Does
Journal:  BMC Psychiatry       Date:  2018-12-12       Impact factor: 3.630

4.  Factors influencing cognitive reactivity among young adults at high risk for depression in China: a cross-sectional study.

Authors:  Fei Fei Huang; Zhi Peng Wen; Qi Li; Bin Chen; Wen Jie Weng
Journal:  BMC Public Health       Date:  2020-05-15       Impact factor: 3.295

5.  The measurement of cognitive reactivity to sad mood in patients remitted from major depressive disorder.

Authors:  Caroline A Figueroa; Roel J T Mocking; Gelera A Mahmoud; Maarten W Koeter; Claudi L Bockting; Willem van der Does; Henricus G Ruhe; Aart H Schene
Journal:  Br J Clin Psychol       Date:  2018-02-27

6.  Personalized ESM monitoring and feedback to support psychological treatment for depression: a pragmatic randomized controlled trial (Therap-i).

Authors:  H Riese; L von Klipstein; R A Schoevers; D C van der Veen; M N Servaas
Journal:  BMC Psychiatry       Date:  2021-03-10       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.